Trial Profile

An Open-label Phase 2, Multicenter, Open-Label Clinical Study to Evaluate the Safety and Efficacy of ABSK061 and ABSK043 With or Without Chemotherapy in Patients With Metastatic/Unresectable Solid Tumors With FGFR2/3 Alterations

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 13 Apr 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ABSK 043 (Primary) ; ABSK 061 (Primary) ; Capecitabine; Oxaliplatin
Indications Carcinoma; Gastric cancer; Non-small cell lung cancer; Oesophageal cancer; Solid tumours; Urogenital cancer
Focus Adverse reactions; Therapeutic Use
Sponsors Abbisko Therapeutics

31 Mar 2026 According to Abbisko Therapeutics media release, the company plans to enroll US patients into the trial.
19 Mar 2026 According to Abbisko Therapeutics media release, preliminary data are expected to be reported in the second half of 2026.
19 Nov 2024 Status changed from not yet recruiting to recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com